Evelyn M. Horn
Advanced in Transthyretin Amyloidosis

Dr. Evelyn M. Horn

Advanced Heart Failure and Transplant Cardiology | Cardiology
Weill Medical College Of Cornell
520 E 70th St, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Transthyretin Amyloidosis
Weill Medical College Of Cornell
520 E 70th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Evelyn Horn is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in New York, New York. Dr. Horn is rated as an Advanced provider by MediFind in the treatment of Transthyretin Amyloidosis. Her top areas of expertise are Pulmonary Hypertension, Hypertension, Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Transplant, and Aortic Valve Replacement.

Her clinical research consists of co-authoring 124 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Transthyretin Amyloidosis.

Specialties
Advanced Heart Failure and Transplant Cardiology
Cardiology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
520 E 70th St, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Tricuspid Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System and Optimal Medical Therapy (OMT) Compared to OMT Alone in Patients With Tricuspid Regurgitation
A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Tricuspid Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System and Optimal Medical Therapy (OMT) Compared to OMT Alone in Patients With Tricuspid Regurgitation
Enrollment Status: Recruiting
Publish Date: January 21, 2026
Intervention Type: Device, Drug
Study Phase: Not Applicable
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Enrollment Status: Terminated
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
Clinical Study of the BioVentrix Revivent TC™ System for Treatment of Left Ventricular Aneurysms (ALIVE)
Clinical Study of the BioVentrix Revivent TC™ System for Treatment of Left Ventricular Aneurysms (ALIVE)
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
Sensible Medical Innovations (Noninvasive) Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients- a Randomized Controlled Study
Sensible Medical Innovations (Noninvasive) Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients- a Randomized Controlled Study
Enrollment Status: Terminated
Publish Date: December 29, 2017
Intervention Type: Device
Study Phase: Not Applicable
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Enrollment Status: Terminated
Publish Date: June 23, 2017
Intervention Type: Device
Study Phase: Phase 3
View 10 Less Clinical Trials

122 Total Publications

Prevalence and Clinical Implications of Excess Adiposity in Group 1 Pulmonary Hypertension.
Prevalence and Clinical Implications of Excess Adiposity in Group 1 Pulmonary Hypertension.
Journal: Circulation. Heart failure
Published: December 03, 2025
Similar Doctors
Mathew S. Maurer
Elite in Transthyretin Amyloidosis
Dr. Mathew S. Maurer
Advanced Heart Failure and Transplant Cardiology | Cardiology
Elite in Transthyretin Amyloidosis
Dr. Mathew S. Maurer
Advanced Heart Failure and Transplant Cardiology | Cardiology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (5.3 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mathew Maurer is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in New York, New York. Dr. Maurer is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloidosis. His top areas of expertise are Cardiac Amyloidosis, Primary Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Heart Transplant, and Transcatheter Aortic Valve Replacement (TAVR).

Bokhari Sabahat
Distinguished in Transthyretin Amyloidosis
Dr. Bokhari Sabahat
Cardiology
Distinguished in Transthyretin Amyloidosis
Dr. Bokhari Sabahat
Cardiology

Office

210 Somerset St, 
New Brunswick, NJ 
 (32.2 miles away)
908-257-0311
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bokhari Sabahat is a Cardiologist in New Brunswick, New Jersey. Dr. Sabahat is rated as a Distinguished provider by MediFind in the treatment of Transthyretin Amyloidosis. His top areas of expertise are Cardiac Amyloidosis, Primary Amyloidosis, Transthyretin Amyloidosis, Aortic Valve Replacement, and Heart Transplant.

Distinguished in Transthyretin Amyloidosis
Dr. John Vest
Cardiology
Distinguished in Transthyretin Amyloidosis
Dr. John Vest
Cardiology

Office

630 W 168th St # 3347, 
New York, NY 
 (5.1 miles away)
212-305-8194
Languages Spoken:
English
See accepted insurances

John Vest is a Cardiologist in New York, New York. Dr. Vest is rated as a Distinguished provider by MediFind in the treatment of Transthyretin Amyloidosis. His top areas of expertise are Primary Amyloidosis, Transthyretin Amyloidosis, Cardiac Amyloidosis, and Familial Transthyretin Amyloidosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Horn's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile